Skip to main content
Search
Search
Advanced Search
Skip main navigation
Free access
Research Article
29 August 2018

Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data

Authors: Joshua J Gagne [email protected], Theodore Tsacogianis, Sara Bruce Wirta, James R Rogers, Frederico Calado, Chun-Lan Chang, Stuart J Turner, Raymond G Schlienger, Bogdan Balas, Abdurrahman Abdurrob, Mehdi Najafzadeh, and Shirley V WangAuthor Info & Affiliations
Publication: J. Comp. Eff. Res.
Volume 7, Number 11
https://doi.org/10.2217/cer-2017-0088
PDFFormats

Abstract

Aim: We examined characteristics of early sacubitril/valsartan users in a large US electronic health records database. Patients & methods: We identified three cohorts of patients with heart failure (HF): sacubitril/valsartan patients with a prior HF diagnosis; patients with HF with reduced ejection fraction; and patients with HF treated with an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker and a β-blocker. Results: Sacubitril/valsartan patients were younger than patients in the other cohorts; the mean age of sacubitril/valsartan patients increased by 2 years in the first 15 months of marketing. Most sacubitril/valsartan patients had prior use of HF treatment. Conclusion: Overall, sacubitril/valsartan patients resembled those in the HF with reduced ejection fraction cohort, and commonly used other drugs for HF.

Supplementary Material

File (supplementarymaterial.docx)

References

Papers of special note have been highlighted as: • of interest
1.
McMurray JJV, Packer M, Desai AS et al. PARADIGM-HF investigators and committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371(11), 993–1004 (2014).
PubMed
Google Scholar
• Pivotal randomized trial demonstrating effectiveness of sacubitril/enalapril.
2.
Yancy CW, Jessup M, Bozkurt et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 134(13), e298 (2016).
PubMed
Google Scholar
• Heart failure guidelines recommending use of sacubitril/enalapril.
3.
Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin. Pharmacol. Ther. 90(6), 777–790 (2011).
PubMed
Google Scholar
4.
Gagne JJ, Bykov K, Willke RJ, Kahler KH, Subedi P, Schneeweiss S. Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research. Value Health 16(6), 1054–1062 (2013).
PubMed
Google Scholar
5.
Kim CH, Al-Kindi SG, Jandali B, Askari AD, Zacharias M, Oliveira GH. Incidence and risk of heart failure in systemic lupus erythematosus. Heart 103(3), 227–233 (2017).
PubMed
Google Scholar
6.
Al-Kindi SG, ElAmm C, Ginwalla M et al. Heart failure in patients with human immunodeficiency virus infection: epidemiology and management disparities. Int. J. Cardiol. 218, 43–46 (2016).
PubMed
Google Scholar
7.
Mansoor E, Cooper GS. The 2010-2015 prevalence of eosinophilic esophagitis in the USA: a population-based study. Dig. Dis. Sci. 61(10), 2928–2934 (2016).
PubMed
Google Scholar
8.
Lappen JR, Sheyn D, Hackney DN. Does pregnancy increase the risk of abdominal hernia recurrence after prepregnancy surgical repair? Am. J. Obstet. Gynecol. 215(3), 390.e1–5 (2016).
PubMed
Google Scholar
9.
Luo N, Fonarow GC, Lippmann SJ et al. Early adoption of sacubitril/valsartan for patients with heart failure with reduced ejection fraction: insights from Get With the Guidelines – Heart Failure (GWTG-HF). JACC Heart Fail. 5(4), 305–309 (2017).
PubMed
Google Scholar
• Complementary study examining early utilization of sacubitril/enalapril.
10.
Nichols GA, Reynolds K, Kimes TM, Rosales AG, Chan WW. Comparison of risk and re-hospitalization, all-cause mortality, and medical resource utilization in patients with heart failure and preserved versus reduced ejection fraction. Am. J. Cardiol. 116(7), 1088–1092 (2015).
PubMed
Google Scholar
|